⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28195973 | 0.75 | ALDH1A1 (0.47) | — | |
| SCHEMBL99231 | 0.75 | — | — | |
| SCHEMBL1446233 | 0.74 | — | — | |
| SCHEMBL7702357 | 0.72 | — | — | |
| SCHEMBL7702370 | 0.72 | — | — | |
| SCHEMBL828673 | 0.72 | — | — | |
| SCHEMBL30731544 | 0.72 | — | — | |
| SCHEMBL7702355 | 0.72 | — | — | |
| Potassium Ion SCHEMBL7702367 | 0.72 | — | — | |
| SCHEMBL8486814 | 0.72 | ALDH1A1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200060995-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2020-02-27 | — | — | US | disclosed |
| US-20180256517-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2018-09-13 | — | — | US | disclosed |
| US-20180085327-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2018-03-29 | — | — | US | disclosed |
| US-20160361275-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160318847-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2016-11-03 | — | — | US | disclosed |
| US-9458082-B2 | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9422225-B2 | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| EP-2998288-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | Auspex Pharmaceuticals, Inc. (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-1954669-B1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS INC (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20140296339-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2014-10-02 | — | — | US | disclosed |
| US-7456317-B2 | Deuterated venlafaxine derivatives; venlafaxine hydrochloride; pharmacokinetics; antiserotonine agents; drug abuse, drug dependence; monoamine neurotransmitters; for intravenous administration; tablet/capsule form | AUSPEX PHARMACEUTICALS (US) | 2008-11-25 | — | — | US | disclosed |
| CN-101309917-A | Stomach H with enhanced therapeutic properties+，K+-deuteration inhibitors of ATPase | AUSPEX PHARMACEUTICALS INC (US) | 2008-11-19 | — | — | CN | disclosed |
| EP-1951643-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | Auspex Pharmaceuticals Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1934201-A1 | DEUTERATED INHIBITORS OF GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | Auspex Pharmaceuticals Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20070155820-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070149622-A1 | Deuterated venlafaxine derivatives formed by decyclization with formic acid; venlafaxine hydrochloride; pharmacokinetics; antiserotonine agents; drug abuse, drug dependence; monoamine neurotransmitters | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007062119-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070112031-A1 | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| WO-2007041630-A1 | DEUTERATED INHIBITORS OF GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070082929-A1 | Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC. | 2007-04-12 | — | — | US | disclosed |